Publication
Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort.
Hsi-Chen Tsai, Jing-Ren Tseng, Feng-Yuan Liu, Chun-Te Wu, Kai-Jie Yu, Po-Jung Su, Kung-Chu Ho
Annals of nuclear medicineSep 15, 2026PMID 42742906doi:10.1007/s12149-026-02284-z Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260916-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
OBJECTIVE: Real-world outcomes of Ra-223 in Asian populations vary and are influenced by reimbursement policies that restrict use to symptomatic patients. We aimed to identify baseline predictors of treatment completion and overall survival (OS) in metastatic castration-resistant prostate cancer…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.